A practical reference on incretin: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-12-17. Anything still debated is marked as such rather than presented as settled.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Includes the 39-residue backbone and the attached fatty diacid |
| Molecular weight | Approximately 4813 Da | Average mass; the monoisotopic value is slightly lower |
| Receptor targets | GIP receptor and GLP-1 receptor | Dual engagement defines the pharmacological class |
| Backbone length | 39 amino acids | Sequence modified from native glucose-dependent insulinotropic polypeptide |
| Albumin interaction | Reversible, mediated by the fatty diacid | Slows renal clearance and lengthens circulation time |
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
=== Linus Pauling and the molecular clock hypothesis === Zuckerkandl's first project under Pauling (working with graduate student Richard T. Jones) was the application of new protein identification techniques—a combination of paper chromatography and electrophoresis that produced a two-dimensional pattern—to hemoglobin. The peptide fragments of hemoglobin samples from different species, partially broken apart by digestive enzymes, would produce unique patterns that could be used to estimate differences of protein structure. Zuckerkandl, Jones and Pauling published a comparison of several species' hemoglobin identification patterns in 1960, observing that the degree of dissimilarity of protein patterns corresponded approximately to the phylogenetic distance between source species. However, the method was not conducive to quantitative comparisons, so Zuckerkandl began working on the determination of the actual peptide sequence of the α and β chains of human and gorilla hemoglobin. In 1962, Pauling and Zuckerkandl published their first paper using the molecular clock concept (though not yet by that name). Like a number subsequent collaborative papers, it was not peer-reviewed—it was an invited paper in honor of Albert Szent-Györgyi—and they intentionally took the opportunity to "say something outrageous". The paper used the number of differences in the α and β chains of hemoglobin to infer the time since the last common ancestor for a number of species, calibrated based on paleontological evidence for humans and horses.
(2026) recover ancient DNA from mammoth ivory from the Hohle Fels cave (Germany), and report evidence of presence of mammoth specimens from multiple distinct lineages in the studied sample. Zanina et al. (2026) reconstruct the environment and diet of the woolly mammoth calf specimen "Yana" from the Batagay section (Sakha, Russia) on the basis of the study of contents of its gastrointestinal tract and the material found between its forelimbs. A new, nearly complete skeleton of a woolly mammoth, identified as a male aged approximately 30–40 years, is described from the latest Pleistocene strata from the Taymyr Peninsula (Russia) by Petrova et al. (2026). Moots et al. (2026) determine sex of 521 woolly mammoth specimens on the basis of the study of ancient DNA, reporting evidence indicating that mammoths from bone accumulation sites were predominantly female, while mammoths from other depositional settings were predominantly male, and interpret these findings as suggestive of anthropogenic origin of mammoth bone accumulations and of preferential targeting of mammoth females by humans. Hannold et al. (2026) reconstruct the diets of pygmy mammoths from Northern Channel Islands and Columbian mammoths from Rancho La Brea and coastal Santa Barbara in southern California on the basis of stable isotopes in tooth enamel. Evidence from the study of tooth enamel of Columbian mammoths from 14 sites in the Central Basin of Mexico, interpreted as indicative of a generalist diet with varying proportions of C3 and C4 plants, is presented by Rodríguez-Franco et al. (2026).
A cryptocurrency wallet is a device, physical medium, program or an online service which stores the public and/or private keys for cryptocurrency transactions. In addition to this basic function of storing the keys, a cryptocurrency wallet more often offers the functionality of encrypting and/or signing information. Signing can for example result in executing a smart contract, a cryptocurrency transaction (see "bitcoin transaction" image), identification, or legally signing a 'document' (see "application form" image).
Science-Based Medicine emphasized that Ventavia oversaw just three of the 153 clinical sites involved with Pfizer's trial and "a small fraction (~1,000 by the time the whistleblower was fired) of the trial's over ~44,000 subjects." On 10 October 2022, during a session of the European Parliament's Special Committee on the COVID-19 Pandemic, Pfizer executive Janine Small testified that the company had not evaluated the Pfizer–BioNTech COVID-19 vaccine for its ability to reduce transmission of the SARS-CoV-2 virus prior to its release to the general public. Dutch MEP Rob Roos described the admission as "scandalous". CEO Albert Bourla was slated to attend, but withdrew. Roos's statements in turn have been described as "misleading".
The two major inactive metabolites are the N-dealkylation products (the carboxylic acid ID-20219 and the piperazine ID-11614), and a norbornane hydroxylated derivative of ID-20219 (ID-20220). Of lurasidone and its metabolites circulating in the blood, the native drug makes up 11%, the main active metabolite 4%, and the inactive carboxylic acids 24% and 11%, respectively. Several dozen metabolites have been identified altogether.:59–61 Biological half-life is given as 18 hours or 20 to 40 hours in different sources. 80% or 67% of a radiolabelled dose was recovered from the feces, and 9% or 19% from the urine.
Sources: en.wikipedia.org
Genes express their functional effect through the production of proteins, which are molecules responsible for most functions in the cell. Proteins are made up of one or more polypeptide chains, each composed of a sequence of amino acids. The DNA sequence of a gene is used to produce a specific amino acid sequence. This process begins with the production of an RNA molecule with a sequence matching the gene's DNA sequence, a process called transcription. This messenger RNA molecule then serves to produce a corresponding amino acid sequence through a process called translation. Each group of three nucleotides in the sequence, called a codon, corresponds either to one of the twenty possible amino acids in a protein or an instruction to end the amino acid sequence; this correspondence is called the genetic code. The flow of information is unidirectional: information is transferred from nucleotide sequences into the amino acid sequence of proteins, but it never transfers from protein back into the sequence of DNA—a phenomenon Francis Crick called the central dogma of molecular biology. The specific sequence of amino acids results in a unique three-dimensional structure for that protein, and the three-dimensional structures of proteins are related to their functions. Some are simple structural molecules, like the fibers formed by the protein collagen. Proteins can bind to other proteins and simple molecules, sometimes acting as enzymes by facilitating chemical reactions within the bound molecules (without changing the structure of the protein itself).
== Applications & Research Fields == Izon’s size-exclusion chromatography qEV isolation platform and tunable resistive pulse sensing instruments are used in the field of extracellular vesicle research and in the development of extracellular vesicle-related biomarkers and diagnostic tests, as well as in the study of antibody preparations, vaccines, lipid nanoparticles, and virus-like particles.
Turtles have two or more accessory urinary bladders, located lateral to the neck of the urinary bladder and dorsal to the pubis, occupying a significant portion of their body cavity. Their bladder is also usually bilobed with a left and right section. The right section is located under the liver, which prevents large stones from remaining in that side while the left section is more likely to have calculi.
Jackson, A. Y. (1943). Banting as an Artist. Ryerson Press. Shaw, Margaret Mason (1976). Frederick Banting. Fitzhenry & Whiteside. ISBN 978-0-88902-229-4. Stevenson, Lloyd (1946). Sir Frederick Banting. Ryerson Press. Harris, Seale (1946). Banting's miracle; the story of the discoverer of insulin. Lippincott. Walters, Eric (2005). Elixir. Puffin Canada. ISBN 978-0-14-301641-0. Raju, T. N. (1998). "The Nobel Chronicles. 1923: Frederick G Banting (1891–1941), John J R Macleod (1876–1935)". Lancet. 352 (9138): 1482. doi:10.1016/s0140-6736(05)61319-0. PMID 9808029. S2CID 54323266. Hudson, R. P. (1979). "New light on the insulin controversy (Frederick G. Banting and J. J. R. Macleod)". Annals of Internal Medicine. 91 (2): 311. doi:10.7326/0003-4819-91-2-311. PMID 380438. Fletcher, K. (2007). "Sir Frederick Banting homestead sold to developer, family outraged". Canadian Medical Association Journal. 176 (12): 1691–92. doi:10.1503/cmaj.070613. PMC 1877854. PMID 17548378. Shampo, M. A.; Kyle, R. A. (2005). "Frederick Banting – Nobel Laureate for Discovery of Insulin". Mayo Clinic Proceedings. 80 (5): 576. doi:10.4065/80.5.576. PMID 15887423. MacLeod, J. B. A. (2006). "Frederick G. Banting: Giving Prospects for Life from the Past to the New Millennium". Archives of Surgery. 141 (7): 705–07. doi:10.1001/archsurg.141.7.705. PMID 16847245. Elliot, J. C. (2004). "Banting – a Nobel artist". The Medical Journal of Australia. 181 (11–12): 631. doi:10.5694/j.1326-5377.2004.tb06494.x. PMID 15588191. S2CID 10131078. Todhunter, E. N. (1953). "Frederick G.
Sources: en.wikipedia.org
carbamazepine, phenytoin gastric acid suppressants: antacids, antimuscarinics, histamine H2 blockers, proton pump inhibitors sucralfate rifampin, rifabutin, isoniazid efavirenz, nevirapine Ritonavir (an antiretrovial medication), is known for increasing the activity of ketoconazole. So it is recommended to reduce dosage. There is also a list of drugs which significantly decrease systemic exposure to the ketoconazole and drugs whose systemic exposure is increased by the ketoconazole.
== Uses == Irradiation is used to reduce or eliminate pests and the risk of food-borne illnesses as well as prevent or slow spoilage and plant maturation or sprouting. Depending on the dose, some or all of the organisms, microorganisms, bacteria, and viruses present are destroyed, slowed, or rendered incapable of reproduction. When targeting bacteria, most foods are irradiated to significantly reduce the number of active microbes, not to sterilize all microbes in the product. Irradiation cannot return spoiled or over-ripe food to a fresh state. If this food was processed by irradiation, further spoilage would cease and ripening would slow, yet the irradiation would not destroy the toxins or repair the texture, color, or taste of the food. Irradiation slows the speed at which enzymes change the food. By reducing or removing spoilage organisms and slowing ripening and sprouting (e.g. potato, onion, and garlic) irradiation is used to reduce the amount of food that goes bad between harvest and final use. Shelf-stable products are created by irradiating foods in sealed packages, as irradiation reduces chance of spoilage, the packaging prevents re-contamination of the final product. Foods that can tolerate the higher doses of radiation required to do so can be sterilized. This is useful for people at high risk of infection in hospitals as well as situations where proper food storage is not feasible, such as rations for astronauts.
Most dwarf gouramis live for about four to six years; with proper care, they can live longer. Dwarf gouramis are generally peaceful, but can be slightly territorial. They do well in most community aquariums. Temperatures of 27 °C (81 °F) are easily tolerated. Dwarf gouramis raised for aquarium trade in Singapore may carry dwarf gourami iridovirus. Recent research has shown that 22% of Singapore Trichogaster lalius carry this virus. Dwarf gouramis are often confused with the closely related thick-lipped gouramis at a younger age and are sometimes sold together.
In April 2025, Eli Lilly, represented by Kirkland & Ellis and Walsh Pizzi O'Reilly Falanga, filed a series of lawsuits in federal courts in New Jersey and California against several telehealth and compounding pharmacy companies, including Willow Health Services, Henry Meds, Mochi Health, Fella Health, and Empower Clinic Services, alleging unfair competition, false advertising, and deceptive business practices related to the sale of unapproved compounded tirzepatide products marketed for weight loss. The company argued that the defendants sold compounded versions of tirzepatide without FDA approval or adequate testing and falsely claimed that their products were safe, effective, and superior to Lilly's FDA-approved drugs Mounjaro and Zepbound. The defendants disputed the claims, characterising the lawsuits as an attempt by Eli Lilly to restrict competition and limit patient and provider choice in the weight-loss drug market. In August 2025, U.S. District Judge Karen Marston issued the first substantive rulings in that multidistrict litigation, dismissing several claims while allowing the core allegations to proceed. The court rejected portions of the plaintiffs' misrepresentation, medical monitoring, and design defect claims, but allowed claims alleging that Novo Nordisk and Eli Lilly failed to adequately warn patients about gastrointestinal risks on drug labels to move forward. The litigation at that stage encompassed more than 2,600 individual lawsuits involving Ozempic, Mounjaro, and related GLP-1 receptor agonist drugs.
== Notes == a "Points" refers to carry-over points accrued following the sanction. For example, 154.69 points draw a one-match suspension, with 54.69 carry-over points (for every 100 points, a one-match suspension is given). s Denotes amount of seasons on the Essendon list only.
Sources: en.wikipedia.org
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.
Engaging two receptors recruits signaling pathways that only partly coincide. This can shift the magnitude of effects on insulin release, glucagon levels and appetite relative to selective agents. Whether the pairing delivers benefits beyond a simple sum of the two is still debated in the literature.
The proportional contribution of each receptor to observed clinical effects has not been fully separated. Long-term consequences of continuous dual stimulation are likewise unclear. Investigators continue to probe these points through laboratory and clinical work.
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.